Verdiperstat Drug Asset Due Diligence Report 2026

This Verdiperstat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 1

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Verdiperstat can convert its Small molecule drug profile and MPO biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Verdiperstat (query alias: verdiperstat)
Modality / target	Small molecule drug; MPO; MPO inhibitors
Highest global status	Phase 1
Originator	AstraZeneca PLC
Active developers	University of California, West Virginia University, Biohaven Pharmaceuticals, Inc.

The MCP disease footprint includes Aphasia, Primary Progressive, Pancreatic Ductal Adenocarcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04436510	Phase 2/3	Completed	167	Disease Progression as Assessed by the ALSFRS-R-Slope
NCT05184569	Phase 1	Active, not recruiting	64	Incidence of Treatment-Emergent Adverse Events
NCT04616456	Early Phase 1	Completed	19	standardized uptake values (SUV)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects With Multiple System Atrophy (M-STAR Study)

Phase 3; n=421; evaluation: not stated. Reported fields: Change From Baseline in the Modified UMSARS Score at Week 48(Least Squares Mean) = 5.20 units on a scale (95% Confidence Interval, 4.52 - 5.89); Change From Baseline in the Modified UMSARS Score at Week 48(Least Squares Mean): Least Square mean difference = 0.35(95% CI, -0.60 to 1.30), P-Value = 0.4656; Change From Baseline in the Modified UMSARS Score at Week 48(Least Squares Mean): Least Square mean difference = 0.35(95% CI, -0.60 to 1.30), P-Value = 0.4656

HEALEY ALS Platform Trial - Regimen B Verdiperstat

Phase 2/3; n=167; evaluation: not stated. Reported fields: Disease Progression as Assessed by the ALSFRS-R-Slope(Mean) = -1.05 ALSFRS-R total score points per month (Standard Deviation, 0.086); Disease Progression as Assessed by the ALSFRS-R-Slope(Mean): Disease Rate Ratio = 0.98(95% CI, 0.769 - 1.237); Disease Progression as Assessed by the ALSFRS-R-Slope(Mean): Disease Rate Ratio = 0.98(95% CI, 0.769 - 1.237)

Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)

Phase 2/3; n=not disclosed; evaluation: Negative. Reported fields: ALSFRS-R = Verdiperstat did not statistically differentiate from placebo ; ALSFRS-R = Verdiperstat did not statistically differentiate from placebo

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Verdiperstat addresses Aphasia, Primary Progressive, Pancreatic Ductal Adenocarcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2018-09-05	Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy	Phase 2	Financial terms not disclosed
2018-09-04	Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy	Phase 2	US$112.1M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Process for the preparation of verdiperstat”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION